Terumo announces global commercial launch of K-Pack Embrace™ active safety needle

Terumo Corporation today announced the global commercial launch of its K-Pack Embrace™ active safety needle. The new safety injection needle is packaged in a rigid cap and case container, designed to facilitate the downstream co-packing processes and protect the needle through the product life cycle until the point of use.

K-Pack Embrace™ Active Safety Needle. Image Credit: Terumo Corporation

Co-packing a pre-selected injection needle with a drug product and syringe can significantly reduce the risks to the patient, add convenience for the healthcare professional (HCP) and simultaneously maintain the value proposition of the product for the drug company. Automated co-packing processes require enhanced hard-shell protection of needles for easy handling during co-packing and to maintain needle sterility and performance over the product’s intended shelf life.

The K-Pack Embrace™ active safety needle is designed specifically for automated co-packing processes with its compact hard-shell case. It is intended for subcutaneous (SC), intramuscular (IM) and intravenous (IV) applications and includes Terumo’s T-Sharp™ technology with integrated needle shield safety features.

Available in either 1” (25 mm) or 5/8” (16 mm) lengths, the K-Pack Embrace™ 25-gauge needle is compatible with all ISO 80369-7 male connectors and its color-coded, tamper-evident label includes a 2D barcode (UDI carrier) that supports automated in-line visual inspection.

K-Pack Embrace™ reduces the risk of needle stick injuries with its integrated hinged needle shield, which can be activated with one hand and provides audible, visual and tactile confirmation of engagement.

The K-Pack Embrace™ active safety needle is a great example of applying our Deviceutical™ approach that brings devices and pharmaceuticals together for uniquely integrated injectable drug delivery solutions.”

Nicolas Eon, Global Product Manager, Injection and Infusion Platforms, Pharmaceutical Solutions Division, Terumo Corporation

“The K-Pack Embrace™ design simultaneously protects the healthcare professional, patient and product, all while making the efficiencies of automated co-packing available to our pharmaceutical customers,” continues Marco Chiado Piat, President, Pharmaceutical Solutions Division, Terumo. “This new active safety needle builds protection and safety into a single product that aligns with our goal of producing injectable drug delivery solutions that improve the lives of patients.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Terumo Corporation. (2026, October 06). Terumo announces global commercial launch of K-Pack Embrace™ active safety needle. News-Medical. Retrieved on October 06, 2026 from https://www.news-medical.net/news/20261006/Terumo-announces-global-commercial-launch-of-K-Pack-Embracee284a2-active-safety-needle.aspx.

  • MLA

    Terumo Corporation. "Terumo announces global commercial launch of K-Pack Embrace™ active safety needle". News-Medical. 06 October 2026. <https://www.news-medical.net/news/20261006/Terumo-announces-global-commercial-launch-of-K-Pack-Embracee284a2-active-safety-needle.aspx>.

  • Chicago

    Terumo Corporation. "Terumo announces global commercial launch of K-Pack Embrace™ active safety needle". News-Medical. https://www.news-medical.net/news/20261006/Terumo-announces-global-commercial-launch-of-K-Pack-Embracee284a2-active-safety-needle.aspx. (accessed October 06, 2026).

  • Harvard

    Terumo Corporation. 2026. Terumo announces global commercial launch of K-Pack Embrace™ active safety needle. News-Medical, viewed 06 October 2026, https://www.news-medical.net/news/20261006/Terumo-announces-global-commercial-launch-of-K-Pack-Embracee284a2-active-safety-needle.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Comments are closed

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.